Targretin and Malignant neoplasm progression - a phase IV clinical study of FDA data

Summary:

Malignant neoplasm progression is reported as a side effect among people who take Targretin (bexarotene), especially for people who are male, 60+ old, have been taking the drug for < 1 month also take Valchlor, and have Anaplastic large cell lymphoma t- and null-cell types.

The phase IV clinical study analyzes which people have Malignant neoplasm progression when taking Targretin. It is created by eHealthMe based on reports of 1,056 people who have side effects when taking Targretin from the FDA, and is updated regularly.

What is Targretin?

Targretin has active ingredients of bexarotene. eHealthMe is studying from 1,064 Targretin users. Check the latest studies of Targretin.

What is Malignant neoplasm progression?

Malignant neoplasm progression (cancer tumour came back) is found to be associated with 1,515 drugs and 1,634 conditions by eHealthMe. Check the latest studies of Malignant neoplasm progression.

On Jul, 09, 2026

1,056 people reported to have side effects when taking Targretin.
Among them, 28 people (2.65%) have Malignant neoplasm progression.

Could Targretin cause Malignant neoplasm progression?

Among these 28 people:

How long have people been on Targretin when they have Malignant neoplasm progression? *

What is the gender of people who have Malignant neoplasm progression when taking Targretin? *

female: 42.86 %
male: 57.14 %

What is the age of people who have Malignant neoplasm progression when taking Targretin? *

What are other drugs people take besides Targretin? *

What are other side effects people have besides Malignant neoplasm progression? *

Hypothyroidism (abnormally low activity of the thyroid gland, resulting in retardation of growth and mental development): 10 people, 35.71%
Hypertriglyceridaemia (excess of triglycerides in the blood): 6 people, 21.43%
Cardiac Failure: 4 people, 14.29%
Hyperlipidaemia (presence of excess lipids in the blood): 2 people, 7.14%
Joint Pain: 2 people, 7.14%
Mycosis Fungoides (lymphocytes (a type of white blood cell) become malignant (cancerous) and affect the skin): 2 people, 7.14%
Fatigue (feeling of tiredness): 2 people, 7.14%
Rashes (redness): 2 people, 7.14%
Metastases To Liver (cancer spreads to liver): 2 people, 7.14%
Constipation: 2 people, 7.14%

What are the existing conditions these people have? *

Mycosis Fungoides (lymphocytes (a type of white blood cell) become malignant (cancerous) and affect the skin): 3 people, 10.71%
Anaplastic Large Cell Lymphoma T- And Null-Cell Types (t-cell or null-cell cancer, a type of blood cancer): 3 people, 10.71%
Thyroid Cancer: 1 person, 3.57%
Reflux Gastritis (a condition in which the lining of a person's stomach becomes inflamed as a result of exposure to bile): 1 person, 3.57%
Pancreatic Carcinoma (pancreatic cancer): 1 person, 3.57%
Pain: 1 person, 3.57%
Hypothyroidism (abnormally low activity of the thyroid gland, resulting in retardation of growth and mental development): 1 person, 3.57%
High Blood Pressure: 1 person, 3.57%
Headache (pain in head): 1 person, 3.57%
Dyslipidaemia (abnormal amount of lipids): 1 person, 3.57%

* Approximation only. Some reports may have incomplete information.

Do you take Targretin and have Malignant neoplasm progression?

- Check whether Malignant neoplasm progression is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Targretin:

Targretin (1,064 reports)

Browse all side effects of Targretin:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Malignant neoplasm progression:

Malignant neoplasm progression (1,515 drugs)

Browse all the conditions that are associated with Malignant neoplasm progression:

Malignant neoplasm progression (1,634 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on bexarotene (the active ingredients of Targretin) and Targretin (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.